These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25794833)

  • 1. Uncovering the metabolic complications of androgen deprivation therapy in patients with prostate cancer--where do we take it next?
    Pinthus JH
    J Urol; 2015 Jun; 193(6):1882-3. PubMed ID: 25794833
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
    Tsai HT; Keating NL; Van Den Eeden SK; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Smith MR; Potosky AL
    J Urol; 2015 Jun; 193(6):1956-62. PubMed ID: 25524243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications.
    Tzortzis V; Samarinas M; Zachos I; Oeconomou A; Pisters LL; Bargiota A
    Hormones (Athens); 2017 Apr; 16(2):115-123. PubMed ID: 28742500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy for prostate cancer: new concepts and concerns.
    Smith MR
    Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):247-54. PubMed ID: 17940447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term androgen deprivation therapy in prostate cancer.
    Ockrim JL; Abel PD
    BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586
    [No Abstract]   [Full Text] [Related]  

  • 8. Complications of androgen-deprivation therapy in prostate cancer: the other side of the coin.
    Hoffmann P; Schulman C
    BJU Int; 2009 Apr; 103(8):1020-3. PubMed ID: 19348058
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer.
    Torimoto K; Samma S; Kagebayashi Y; Chihara Y; Tanaka N; Hirayama A; Fujimoto K; Hirao Y
    Jpn J Clin Oncol; 2011 Apr; 41(4):577-81. PubMed ID: 21297122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological treatment of patients with advanced prostate cancer.
    Turner B; Drudge-Coates L
    Nurs Stand; 2014 Feb; 28(23):44-8. PubMed ID: 24494915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing, but under-recognized problem.
    Brown JE; Sherriff JM; James ND
    BJU Int; 2010 Apr; 105(8):1042-3. PubMed ID: 20201833
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognised problem.
    Langley R; Price P; Pollock P; Abel PD
    BJU Int; 2010 Sep; 106(5):726-7; author reply 727. PubMed ID: 21050352
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
    Miller K
    Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.
    Morote J; Gómez-Caamaño A; Alvarez-Ossorio JL; Pesqueira D; Tabernero A; Gómez Veiga F; Lorente JA; Porras M; Lobato JJ; Ribal MJ; Planas J;
    J Urol; 2015 Jun; 193(6):1963-9. PubMed ID: 25541340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abiraterone and MVD3100 take androgen deprivation to a new level.
    Schmidt C
    J Natl Cancer Inst; 2011 Feb; 103(3):175-6. PubMed ID: 21242338
    [No Abstract]   [Full Text] [Related]  

  • 20. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer.
    Gild P; Cole AP; Krasnova A; Dickerman BA; von Landenberg N; Sun M; Mucci LA; Lipsitz SR; Chun FK; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Trinh QD
    J Urol; 2018 Sep; 200(3):573-581. PubMed ID: 29673944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.